Pediatric subjects participating in HHS-funded or FDA-regulated studies are afforded additional protections not codified in subpart A of the Federal…
Read MorePRIM&R recently submitted comments in response to the Food and Drug Administration (FDA)’s proposed rule "Institutional Review Board Waiver or…
Read More
At the 2017 Advancing Ethical Research Conference (AER17), I caught the plenary session, “New Frontiers: The Changing Landscape of Research…
Read MoreIn June 2017, PRIM&R hosted the webinar series Focus on the Revised Common Rule. Comprising four sessions on the topics…
Read Moreby David R. Van Houten, MS, research integrity advocate During PRIM&R’s Best Practices for Assessing Risk in Social and Behavioral…
Read More